Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.32 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22751713 | 0.93 | ALKBH5 (0.32) | MAPTALKBH5FTOKDM4EMEN1 | |
| SCHEMBL22751659 | 0.90 | BCHE (0.30) | MAPTLMNABCHEACHEHTT | |
| SCHEMBL22751681 | 0.88 | KDM4E (0.33) | MAPTALKBH5FTOKDM4EMEN1 | |
| SCHEMBL22751688 | 0.87 | BCHE (0.32) | MAPTLMNASMN1; SMN2ALKBH5FTO | |
| SCHEMBL22751708 | 0.86 | LMNA (0.31) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL22751668 | 0.84 | — | — | |
| SCHEMBL22751655 | 0.81 | MAPT (0.33) | MAPTLMNASMN1; SMN2ALKBH5FTO | |
| SCHEMBL22751712 | 0.81 | ALKBH5 (0.30) | ALKBH5FTO | |
| SCHEMBL22751665 | 0.80 | KDM4E (0.33) | MAPTALKBH5FTOKDM4EMEN1 | |
| SCHEMBL22751705 | 0.80 | MEN1 (0.30) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10862050-B2 | Heterocyclic compound and organic electroluminescence device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10862050-B2 | Heterocyclic compound and organic electroluminescence device including the same | CCNT1, CCNL2, CCNA1 | MAPT 1587/4885LMNA 2930/4885SMN1; SMN2 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.